AIPM took part in a press conference on the opening of joint production of IPSEN and "Raduga Production" (ROSTA)

The opening ceremony was held with participation of Olga Kazanskaya, Vice-Governor of Saint Petersburg, Marc de Garidel, Chairman of Board and Chief Executive Officer of IPSEN, David Panikashvili, President of Pharmaceutical Group ROSTA, Marina Veldanova, Head of representative office of IPSEN in Russia, Vladimir Shipkov, Executive Manager of Association of International Pharmaceutical Manufacturers (AIPM), Jean-Maurice Ripert, Ambassador of France in Russia and recognized experts of pharmaceutical sector.
 

 “Localization of international manufacturing in Russia is a logical and important step on the way of national pharmaceutical industry formation, aimed at increasing of availability of highly efficient and high quality drugs for the people of our country. In addition, it also brings additional jobs for training of the dedicated experts”, - said the President of PG ROSTA David Panikashvili to comment the set up of а new cooperation. 

The Chairman of Board and Chief Executive Officer of IPSEN Marc de Garidel, in his turn, stressed, that Russia is a key country for IPSEN from the point of view of future development and opportunities for growth.  

“We regularly increased the sales in Russia over the last years. However we needed to expand the business for implementation of the whole set of capabilities. We considered the option to execute a partner agreement with the Russian company, and, as a result, we chose the most efficient way at this stage, having entered into cooperation with ROSTA, which high-tech site we use to launch the manufacturing of our products now”, - he said.

The production cycle of the drug Tanakan® at the facilities of “Raduga Production” plant is designed in two stages. The first one is a stage of manufacturing of the secondary package for the drug, where 2 million packages are planned to be produced during the first year of operation. The second stage is intended to launch the full cycle manufacturing of tablets with the planned annual output of 120 million tablets.

According to the Manager of Russian representative office of IPSEN Marina Veldanova, - “partnership with ROSTA - one of the leaders of Russian pharmaceutical market, and launch of local manufacturing of the drugs is a result of many years of fruitful work and one more proof of high priority of the Russian market for IPSEN”.

“Following the strategic line of development of pharmaceutical sector of our country, the localization give us new horizons of development and helps taking one more step towards our patients”, - she said.

The Ambassador of France in Russia, Mr. Jean-Maurice RIPERT encouraged the cooperation between the French and Russian companies: “There are few countries, which companies invest and create the manufacturing enterprises in Russia more than the French companies do now, especially in pharmaceutical industry. We are very happy that France was ranked the 4^th by foreign investments in Russia upon the results of 2014. Moreover, it was the first without consideration of territories applying the attractive taxation regime”.

Vladimir Shipkov, AIPM Executive Director, pointed out that member companies of the Association invested more than USD 2 billion in localization of various forms, and these processes were ultimately determinative for the establishment of the Russian pharmaceutical industry and laid the ground for its further development.

“The partnership between the international and Russian companies in the field of drugs manufacturing is a significant and mutually profitable form of business cooperation. Launch of any product within the framework of such a contract manufacturing means, from viewpoint of a Russian patient, the increased availability of modern and efficient therapeutic solutions. We witnessed the implementation of joint project between IPSEN and “Raduga Production” (“ROSTA” Group of Companies) today. The international industry thereby goes on demonstrating by deeds that it’s a reliable partner of the state in provision of high-quality drugs to people of our country, despite the current geopolitical situation and contrary to various speculations and initiatives that degrade the role of innovations in solving of modern healthcare problems”, - commented Vladimir Shipkov.

Evgeny Barantsevich, M.D., Head of Department of Neurology and Manual Therapy in I.P. Pavlov First Saint-Petersburg State Medical University explained what the drug Tanakan was: “The composition of Tanakan®represents a complex mix of many active substances. It has rather wide range of indications for use such as cognitive and sensorineural deficiency of various genesis (except for Alzheimer disease and dementia of various etiology); vision disorder of vascular genesis, decrement in visual acuity; hearing disorder, tinnitus, dizziness and disturbance of muscular coordination, primarily of vascular genesis, Raynaud disease and syndrome; Charcot syndrome at chronic obliterant arteriopathy of lower extrimities (2 degrees according to Fontaine). The drug increases the blood supply of the brain due to improvement of microcirculation, and can normalize the tonus of arteries and veins. Tanakan is a completely special drug with the unique comprehensive effect”.